Richard Bardales
Cardiovascular Disease · Lancaster, OHNPI 1619978889
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,335 of the $7,599 with a category attached, or 70.2%. Medtronic accounts for 65.9% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $3,445 and has fallen 99.6% since, to $15 in 2025.
Across 207 payments — averaging $36.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Johnson & Johnson$521
- Novartis$312
- Sanofi-aventis U.S. LLC$249
- Amgen$245
- Pfizer$132
- plus $1K from 24 others
What the payments were for
- Travel & lodging$2,22529%
- Food & beverage$5,33570%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 50 | $5,011 |
| Johnson & Johnson | 26 | $521 |
| Novartis | 24 | $312 |
| Sanofi-aventis U.S. LLC | 14 | $249 |
| Amgen | 15 | $245 |
| Pfizer | 8 | $132 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $115 |
| AstraZeneca(2 entities) | 7 | $109 |
| Boehringer Ingelheim | 5 | $94 |
| Amarin Pharma, Inc. | 5 | $88 |
| Bayer | 6 | $87 |
| Kowa Pharmaceuticals America, Inc. | 6 | $82 |
| Alnylam Pharmaceuticals Inc. | 4 | $76 |
| Regeneron Healthcare Solutions, Inc. | 4 | $64 |
| Lundbeck LLC | 3 | $62 |
| Astellas Pharma US Inc | 4 | $55 |
| Novo Nordisk | 2 | $33 |
| OPKO Pharmaceuticals, LLC | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
| Merck | 2 | $25 |
| Atricure, Inc. | 1 | $25 |
| Aurinia Pharma U.S., Inc. | 1 | $22 |
| Bardy Diagnostics, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Calliditas Therapeutics US Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $15 |
| Baxter Healthcare | 1 | $15 |
| Boston Scientific | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reveal LINQ$580
- LINQ II$362
- Micra$253
- Crome$130
- XARELTO$125
How this compares
$7,599 in reported general payments places this provider in the 80th percentile of 827 cardiovascular disease providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 17 | $351 |
| Carvedilol | 20 | $264 |
| Atorvastatin Calcium | 12 | $156 |
| Amlodipine Besylate | 23 | $128 |
| Metoprolol Succinate | 13 | $56 |
| Lisinopril | 13 | $50 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Lancaster
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Kamal ShemisaCincinnati$314K
- Mehdi ShishehborElyria$237K
- Abdu HawwaGarfield Hts$234K
- Jayanta MukherjeeColumbus$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.